Navigation Links
Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
Date:12/10/2008

SAN CARLOS, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced positive results from the Phase 1 trial of recombinant, secreted protein, NU206, the company's lead compound from its Wnt Therapeutics Program. This single-center, double-blind, placebo-controlled, single-ascending dose (SAD) trial tested the safety, tolerance and pharmacokinetics of a single intravenous (IV) administration of NU206, in 32 healthy male volunteers. Participants were enrolled in four cohorts of varying doses, with a maximum dose of 0.20 mg/kg/day. NU206 had a favorable safety profile, no serious adverse events were observed, and pharmacokinetics were predictable.

"Based on preclinical studies, we believe that NU206 promotes cell growth and repair, and, based also on results from this Phase 1 trial, believe it has the potential to offer a novel approach for the treatment of serious medical conditions such as gastrointestinal (GI) injury, inflammatory bowel disease, and bone disease," said Dr. Ted W. Love, chairman and chief executive officer of Nuvelo. "Because Nuvelo is in the process of merging with ARCA biopharma to create a cardiovascular-focused company, we are currently evaluating partnership and out-licensing opportunities for NU206 to continue development of the compound."

About NU206

NU206 (R-spondin1) is a recombinant, secreted protein that acts as a key regulator of the Wnt pathway, the critical pathway that stimulates cell growth and differentiation during homeostasis and pathogenesis in specific tissues including the GI epithelium and bone. Preclinical studies suggest it can promote growth and repair in animal models of radiation or cancer chemotherapy induced GI injury, inflammatory bowel disease, and bone disease.

About Nuvelo and Kyowa Hakko Kirin's Joint Collaborati
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
2. Nuvelo Reports Second Quarter 2008 Financial Results
3. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
4. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
5. Nuvelo and ARCA biopharma Advance Toward Completion of Merger
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014  MEI Pharma, Inc. (Nasdaq: MEIP ), ... therapies for cancer, announced today that Daniel P. Gold ... BioCentury,s NewsMakers in the Biotech Industry conference on ... the Millennium Broadway Hotel & Conference Center in ... can be accessed at www.meipharma.com . A replay will ...
(Date:9/18/2014)... Pennsylvanie, 18 septembre 2014 Mapi, ... en 1974, a été depuis 40 ans ... évaluations cliniques traditionnelles par des évaluations recentrées ... sur les impacts économiques des traitements. ... A cours d,une récente conférence ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 SeqLL ... Sequencing (tSMS™) technology, announced today the closing of ... investment, led by Genomic Diagnostic Technologies, will increase ... diagnostic applications. , Founded in March 2013 by ... Bioinformatics Analyst at Helicos BioSciences, SeqLL has continued ...
(Date:9/18/2014)... to weight loss and diabetes prevention, could actually hasten ... they do it in a surprising way: by changing ... the substantial population of bacteria residing in our intestines. ... humans, were published today in Nature . Among ... Institute,s Immunology Department, who led this research together with ...
Breaking Biology Technology:MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 31974 - 2014 - Mapi fête ses 40 ans 2SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3
... April 4, 2012 Lixte Biotechnology Holdings, Inc. announced ... States Patent and Trademark Office for its lead histone ... Dr. John Kovach, founder and president of Lixte, ... of skin lymphomas and many other HDACi in various ...
... brain tumors with a combination of chemotherapy and radiation ... than two years after diagnosis. The effectiveness of the ... healthy brain tissue, which restricts chemotherapy access to the ... To address this challenge, researchers from the Georgia ...
... professor in the Department of Mechanical, Aerospace, and Nuclear ... Faculty Early Career Development Award (CAREER) from the National ... $500,000 award to further his research into the design ... CAREER Award is given to faculty members at the ...
Cached Biology Technology:Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor 2Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor 3Novel compound halts tumor spread, improves brain cancer treatment in animal studies 2Novel compound halts tumor spread, improves brain cancer treatment in animal studies 3Novel compound halts tumor spread, improves brain cancer treatment in animal studies 4Rensselaer professor Jie Lian receives NSF CAREER Award 2
(Date:9/18/2014)... stressed they are often grouchy, grumpy, nasty, distracted or ... EPFL have just highlighted a fundamental synaptic mechanism that ... of social skills and cognitive impairment. When triggered by ... the brain. This was revealed by a work published ... team went to look for answers in a region ...
(Date:9/17/2014)... care to reproductive technologies, the justice and well-being ... people to identify key issues, articulate their values ... the most defensible ways forward. But what are ... conversations?, The Hastings Center and the Presidential Commission ... up to publish a series of essays to ...
(Date:9/17/2014)... 2014) A rare genetic disorder known as Jacobsen syndrome ... joint investigation by researchers at San Diego State University ... to suggesting better treatment options for people with Jacobsen ... genetic underpinnings of autism., Jacobsen syndrome affects approximately 1 ... Health. It occurs in a person when there is ...
Breaking Biology News(10 mins):How stress tears us apart 2Why bioethics literacy matters 2Why bioethics literacy matters 3A link between Jacobsen syndrome and autism 2
... Fla. Imagine a chemistry professor and a neuroscientist ... Alzheimer,s disease, or a biomedical engineer working with an ... the University of Florida, teamwork is often considered the ... than that, novel collaborations can inspire students who are ...
... The Howard Hughes Medical Institute (HHMI) today announced new ... undergraduate and precollege science education nationwide. The resources will ... most creative ideas by developing new ways to teach ... HHMI is making the awards through its Precollege and ...
... a popular species of game fish in Lake Erie are ... most comprehensive to date on mercury levels in Great Lakes ... a semi-monthly journal. Satyendra Bhavsar and colleagues note ... lakes in the world. The lakes are of significant economic ...
Cached Biology News:HHMI awards $1.2 million to UF for undergrad education 2HHMI awards $79 million for science education to research universities, top scientists 2HHMI awards $79 million for science education to research universities, top scientists 3HHMI awards $79 million for science education to research universities, top scientists 4HHMI awards $79 million for science education to research universities, top scientists 5
Mouse monoclonal [3B6] to HSV1 + HSV2 ICP5 Major Capsid Protein ( Abpromise for all tested applications)....
Mouse monoclonal [SPM302] to BCAR1, prediluted ( Abpromise for all tested applications). entrezGeneID: 9564 SwissProtID: P56945...
...
p21 Ras Immunogen: Recombinant C-H-ras p21(val-12). Storage: 4 C...
Biology Products: